# Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

> **NCT02297698** · PHASE2 · COMPLETED · sponsor: **Cancer Insight, LLC** · enrollment: 100 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** NeuVax vaccine
- **DRUG:** Trastuzumab
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT02297698
- **Lead sponsor:** Cancer Insight, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297698, "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02297698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*